| Literature DB >> 28018355 |
Austin W Boesch1, Nana Yaw Osei-Owusu2, Andrew R Crowley2, Thach H Chu1, Ying N Chan1, Joshua A Weiner1, Pranay Bharadwaj2, Rufus Hards3, Mark E Adamo4, Scott A Gerber5, Sarah L Cocklin6, Joern E Schmitz6, Adam R Miles7, Joshua W Eckman7, Aaron J Belli8, Keith A Reimann8, Margaret E Ackerman9.
Abstract
Antibodies raised in Indian rhesus macaques [Entities:
Keywords: Fc receptor; IgG; effector function; non-human primate; rhesus
Year: 2016 PMID: 28018355 PMCID: PMC5153528 DOI: 10.3389/fimmu.2016.00589
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1Sequence and structural differences between human and . (A) Sequence alignment of human IgG subclasses with the recombinant monoclonal rhesus macaque IgG. CH2 and CH3 domains are denoted in gray, whereas the N-linked glycosylation site and known human IgG Fc gamma receptors (FcγR) contact residues (35–38) are annotated in blue. (B) Structural model of human IgG1 CH2 and CH3 domains (ribbon) in complex with human FcγRIIIa extracellular domain (space-fill) in which amino acids that differ between rhesus and human IgG1 sequences for each species are colored orange (pdb 1T89). H38Q and oligosaccharides at N297 are illustrated in ball and stick. (C–E). A top-down view of the FcγR binding site, in which conserved positions are colored blue and variant positions colored orange. Oligosaccharides at N297 are illustrated in ball and stick. (C) Positional variance in the FcγR contact interface between human and MM IgG1. (D) Positional variance in the FcγR contact interface among the human IgG subclasses. (E) Positional variance in the FcγR contact interface among MM IgG subclasses. (F) Structural model of human IgG1 (ribbon) in complex with human FcγRIIIa (space-fill) in which amino acids that differ between MM IgG subclasses are colored orange. H38Q is illustrated in ball and stick.
Relative Fc sequence conservation across species.
| MM IgG1 | MM IgG2 | MM IgG3 | MM IgG4 | |
|---|---|---|---|---|
| Hu IgG1 | 90.7 | 88.5 | 89.2 | 88.8 |
| Hu IgG2 | 87.1 | 88.3 | 87.7 | 88.1 |
| Hu IgG3 | 78.5 | 76.4 | 78.2 | 76.4 |
| Hu IgG4 | 87.4 | 87.2 | 89.2 | 90.2 |
| MM IgG1 | – | 89.8 | 91 | 89.2 |
| Hu IgG1 | 90.0 | 89.1 | 90.9 | 92.7 |
| Hu IgG2 | 82.7 | 84.5 | 88.2 | 90.0 |
| Hu IgG3 | 87.3 | 87.3 | 89.1 | 90.9 |
| Hu IgG4 | 85.5 | 86.4 | 91.8 | 93.6 |
| MM IgG1 | – | 90.9 | 92.7 | 90.9 |
Matrix presents the percent identity between the entire Fc and within the CH2 domain only.
Figure 2Recognition of . (A) Recombinant monoclonal rhesus macaque IgG (MM IgG1–4) with minor contamination with dimeric IgG and purified polyclonal rhesus macaque plasma IgG (MM pIgG) were titrated for binding to the high affinity human FcγRI. Triplicates representative of two independent experiments are presented. (B) IgG samples were treated with PNGaseF (blue) or EndoS (red) to remove either all or all but the variably fucosylated GlcNac core of the Fc domain glycan. Triplicate dilutions are presented.
Figure 3Glycosylation state of . (A) Recombinant monoclonal rhesus macaque IgG (MM IgG1–4) with minor contamination with dimeric IgG and purified polyclonal rhesus macaque plasma IgG (MM pIgG) were either untreated or treated with EndoS (red) leaving a variably fucosylated GlcNac core of the Fc domain glycan. Triplicate measurements at 5 × 10−7 M MM IgG1 in one representative multiplex assay are presented. (B,C) IgG glycosylation as determined by glycan HPLC for MM IgG1 (B) and polyclonal IgG derived from MM serum (C). Peak identities were determined by exoglycosidase digests and glycan controls.
Affinity of .
| FcγR | MM IgG1 | MM IgG2 | MM IgG3 | MM IgG4 | |
|---|---|---|---|---|---|
| Experiment 1 | FcγRIIa H131 | 7 ± 1 | 11 ± 4 | 27 ± 9 | 23 ± 5 |
| FcγRIIa R131 | 9 ± 4 | 32 ± 7 | 11 ± 2 | 11 ± 2 | |
| FcγRIIb/c | 36 ± 7 | 90 ± 43 | 46 ± 12 | 33 ± 3 | |
| FcγRIIIa V158 | 4 ± 2 | 21 ± 13 | 84 ± 84 | 32 ± 11 | |
| FcγRIIIa F158 | 4 ± 1 | 48 ± 51 | 78 ± 52 | 48 ± 26 | |
| FcγRIIIb NA1 | 18 ± 7 | 700 ± 430 | 700 ± 430 | 500 ± 370 | |
| FcγRIIIb NA2 | 13 ± 5 | 400 ± 420 | 510 ± 370 | 730 ± 380 | |
| FcγRIIIb SH | 15 ± 8 | 530 ± 340 | 740 ± 370 | 465 ± 400 | |
| Experiment 2 | FcγRIIa H131 | 9 ± 2 | 11 ± 4 | 16 ± 4 | 20 ± 10 |
| FcγRIIa R131 | 21 ± 9 | 41 ± 16 | 25 ± 20 | 20 ± 6 | |
| FcγRIIb/c | 53 ± 14 | 125 ± 37 | 38 ± 7 | 32 ± 7 | |
| FcγRIIIa V158 | 5 ± 2 | 14 ± 11 | 27 ± 33 | 29 ± 17 | |
| FcγRIIIa F158 | 8 ± 2 | 15 ± 4 | 33 ± 4 | 17 ± 1 | |
| FcγRIIIb NA1 | 14 ± 6 | 250 ± 320 | 210 ± 170 | 120 ± 80 | |
| FcγRIIIb NA2 | 15 ± 3 | 32 ± 2 | 270 ± 420 | 270 ± 67 | |
| FcγRIIIb SH | 9 ± 4 | 80 ± 100 | 350 ± 860 | 340 ± 500 |
Binding affinities (.
.
Figure 4Representative surface plasmon resonance (SPR) data and curve fits. Raw SPR signals (black) and kinetic curve fits (red) in a 1:1 model are presented for the Macaca mulatta immunoglobulin G (IgG) subclasses and a purified serum IgG sample for FcγRIIa H131 and FcγRIIIb SH allotypes.
Figure 5Affinity of rhesus immunoglobulin G (IgG) for low affinity human FcγR. (A,B) Equilibrium binding affinity (KD in micromolar) of recombinant monoclonal rhesus IgG subclasses [Macaca mulatta (MM) IgG1–4] as well as a commercially supplied sample of purified polyclonal rhesus macaque plasma IgG (MM pIgG) to the low affinity human FcγR. Bars denote the mean of two to six replicates, in two separate experiments (upper and lower panels) using different preparations of FcγR. (B) Equilibrium binding affinity (KD in micromolar) of 10 randomly selected purified rhesus macaque plasma IgG samples. Bars and whiskers denote the median and interquartile range.
Figure 6Characterization of rhesus immunoglobulin G (IgG) subclass composition and detection reagents. (A,B) Multiplex subclassing assays. (A) Recombinant monoclonal rhesus macaque IgG [Macaca mulatta (MM) IgG1–4] and pooled purified polyclonal rhesus macaque plasma IgG (MM pIgG) were titrated for binding to microspheres conjugated with anti-MM, subclass-specific antibodies (anti-MM IgG1, anti-MM IgG2, anti-MM IgG3), and bound test antibody detected by a pan anti-rhesus IgG detection antibody. (B) In a separate experiment, antibody purified from serum samples from 36 naïve MM (black) was likewise evaluated to detect the presence of IgG1, IgG2, and IgG3 subclasses. (C,D). ELISA subclassing assays. (C) Sensitivity and specificity of MM subclass detection reagents over a titration range when recombinant, CD8α-specific MM IgG subclass antibody test samples were bound to CD8α-conjugated ELISA plates. (D) The composition of MM serum IgG in a pooled sample was evaluated via an ELISA in which either non-specifically adhered serum IgG or recombinant MM IgG subclasses as controls were detected using a dilution series of the anti-subclass detection reagents.
Estimates of subclass prevalences in .
| Animal | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | |
| IgG1 | ++++ | +++++ | ++++ | ++++ | +++ | +++ | ++++ | +++ | +++++ | ++++ | ++++ | ++++ | +++++ | ++++ | ++++ | +++ | ++++ | +++ | ++++ |
| IgG2 | + | ++ | + | + | ++ | + | + | + | ++ | + | ++ | ++ | ++ | ++ | ++ | ++++ | ++ | +++ | ++ |
| IgG3 | nd | nd | nd | nd | nd | nd | * | nd | * | nd | nd | nd | Nd | nd | * | nd | * | * | nd |
| IgG4 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
Response magnitudes are characterized as follows: nd, not observed; *, not quantified; +, <20%; ++, 20–40%; +++, 40–60%; ++++, 60–80%; +++++, 80–100%.
Figure 7Characterization of natural killer (NK) cell degranulation activity of . (A) Subclass-switched forms of the human VRC01 mAb were evaluated in for ability to drive degranulation of NK-92 cells by directly coating a dilution series of IgG onto a 96-well plate. (B) Recombinant rhesus macaque IgG (MM1–4) and polyclonal rhesus macaque plasma IgG (pIgG) was likewise evaluated. Results from an assay with less responsive (left, n = 1) or normally responsive NK-92 cells (right, n = 4) are presented.
Figure 8Characterization of the phagocytic activity of . (A) Exemplary flow cytometry histograms for a titration of MM IgG1 driving phagocytosis of CD8α-conjugated fluorescent beads. (B) Myeloma-derived human IgG1–4 were evaluated in the same assay measuring uptake of fluorescent beads, in this case using beads conjugated with an anti-human Fab reagent. Results from one representative experiment with technical replicates are presented. (C) Recombinant monoclonal rhesus macaque IgG (MM IgG1–4) was evaluated for its ability to drive phagocytosis of CD8α-conjugated fluorescent beads. Representative results from two of five independent experiments in which duplicate titrations were assessed are presented.
Figure 9. A single 50 mg/kg dose of each antibody was administered IV to two normal rhesus macaques, and the change from baseline in absolute number of CD3+CD4− lymphocytes in blood was assessed. Each data point represents the average (n = 2) percent change from baseline (average of two pretreatment measurements).